Placeholder Banner

BIO's Comments on the Expanded CFIUS Review Pilot Program

January 15, 2019

On October 10, the Treasury Department announced the launch of a pilot program implementing certain provisions of the Foreign Investment Risk Review Modernization Act (FIRRMA). FIRRMA made several reforms to the procedures of the Committee on Foreign Investment in the U.S. (CFIUS), the interagency committee tasked with reviewing transactions with foreign investors that may pose national security risks. The pilot program will implement some of these reforms on an expedited basis to enable CFIUS to review foreign investments in “critical technologies” in biotechnology, nanotechnology, and other industries that may pose risks to national security. Because of the pilot’s 30-day effective date, covered transactions will soon be subject to the increased CFIUS review. Accordingly, biotechnology companies should conduct a detailed analysis to determine whether their technologies are captured by the pilot program.

Download Full Comments Below
Final BIO Comment Letter On CFIUS Pilot - 11.9.2018
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
In the wake of the COVID-19 outbreak, the Biotechnology Innovation Organization (BIO) joins 111 industry groups across sectors in a letter to federal, state and local lawmakers supporting uniform definitions of "critical infrastructure" as outlined…